Tuberculosis vaccine in late-stage trial as COVID-19 protection
Texas A&M College of Medicine is leading a consortium of research hospitals and medical schools in a Phase 4 trial to determine if the century-old tuberculosis vaccine can help blunt the damage from COVID-19, at least until a vaccine for the new coronavirus has been proven safe and effective.
"Scientists have known for decades that the tuberculosis vaccine, called bacille Calmette-Guerin, or BCG, improves immunity against some viruses," The Texas Tribune reported back in May, when the trial was just getting started. Jeffrey Cirillo, the Texas A&M microbial pathogenesis and immunology professor who is leading the trial, told Politico on Thursday that about 100 people have already been vaccinated, 200-300 more will get their shots over the next two weeks, and the goal is 1,800 subjects in the "randomized, blinded, placebo-controlled trial."
The TB vaccine has been used more than a billion times around the world, but it's not commonly used in the U.S., except to fight bladder cancer. The researchers at Texas A&M, Baylor College of Medicine, Harvard's School of Public Health, Cedars Sinai Medical Center, and the University of Texas MD Anderson Cancer Center are hoping the vaccine ramps up the immune system to fight off the disease, as it does the cancer cells. A similar trial is being conducted in the Netherlands.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
The U.S. researchers will monitor the volunteers for six months, looking for statistically significant differences between those who get the BCG vaccine and the group that gets a placebo shot. "We're also doing a cognitive study in parallel to evaluate the cognitive effects of COVID-19," Cirillo told Politico's Myah Ward, using before-and-after MRIs and cognitive assessments to see if the vaccine reduces COVID-19's mental impairments. The vaccine is most effective in the first two to three years, he added, and if it is found to be effective, it could be used either as a stop-gap measure until a coronavirus vaccine arrives or in tandem with that vaccine to make it more effective.
Create an account with the same email registered to your subscription to unlock access.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Peter has worked as a news and culture writer and editor at The Week since the site's launch in 2008. He covers politics, world affairs, religion and cultural currents. His journalism career began as a copy editor at a financial newswire and has included editorial positions at The New York Times Magazine, Facts on File, and Oregon State University.
-
Is pop music now too reliant on gossip?
Talking Point Taylor Swift's new album has prompted a flurry of speculation over who she is referring to in her songs
By Richard Windsor, The Week UK Published
-
Nuclear near-misses
The Explainer From technical glitches to fateful split-second decisions, the world has come to the brink of nuclear war more times than you might think
By Rebecca Messina, The Week UK Published
-
What is cloud seeding and did it cause Dubai's severe rainfall?
The Explainer The future is flooded
By Devika Rao, The Week US Published
-
Empty-nest boomers aren't selling their big homes
Speed Read Most Americans 60 and older do not intend to move, according to a recent survey
By Peter Weber, The Week US Published
-
Brazil accuses Musk of 'disinformation campaign'
Speed Read A Brazilian Supreme Court judge has opened an inquiry into Elon Musk and X
By Rafi Schwartz, The Week US Published
-
Disney board fends off Peltz infiltration bid
Speed Read Disney CEO Bob Iger has defeated activist investor Nelson Peltz in a contentious proxy battle
By Rafi Schwartz, The Week US Published
-
Disney and DeSantis reach detente
Speed Read The Florida governor and Disney settle a yearslong litigation over control of the tourism district
By Peter Weber, The Week US Published
-
Visa and Mastercard agree to lower swipe fees
Speed Read The companies will cap the fees they charge businesses when customers use their credit cards
By Peter Weber, The Week US Published
-
Reddit IPO values social media site at $6.4 billion
Speed Read The company makes its public debut on the New York Stock Exchange
By Peter Weber, The Week US Published
-
Housing costs: the root of US economic malaise?
speed read Many voters are troubled by the housing affordability crisis
By Peter Weber, The Week US Published
-
Feds cap credit card late fees at $8
speed read The Consumer Financial Protection Bureau finalized a rule to save households an estimated $10 billion a year
By Peter Weber, The Week US Published